Oxford biotech OMass Therapeutics secures $310 million to advance genetic adrenal disorder program

Oxford-based OMass Therapeutics announced a $310 million private financing round, one of the largest recent fundraises for a UK biotech.

The capital will fund the development of therapies targeting a genetic adrenal disorder, aiming to emulate the success of Neurocrine and Vertex, which previously acquired Crinetics for similar endocrinology work.

The sizable investment reflects strong investor confidence in OMass’s platform and highlights growing interest in rare endocrine disease programs, potentially accelerating its clinical timelines.